Blood Filter Start-Up ExThera Gets Fresenius Backing
This article was originally published in Clinica
Executive Summary
New investor Fresenius Medical Care Ventures GmbH is leading a Series B financing round in ExThera Medical to help fund clinical trials in Germany and the US of the latter’s Seraph Microbind affinity blood filter.
You may also be interested in...
ExThera Blood-Infection Filter Will Get 'Expedited Access' From US FDA
The firm's Seraph 100 blood filter leverages proprietary receptor technology to capture and remove drug-resistant infections and return the blood to the patient with cells intact. FDA says it's a novel enough approach to infections suffered by dialysis patients to be accepted into the Expedited Access Pathway.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.